Glenmark Pharmaceuticals S.a.

Glenmark Pharmaceuticals Limited

Abraham Thomas

Neelima Khairatkar-Joshi

Sukeerthi Kumar

Daisy Manish Shah

Indranil Mukhopadhyay

Sachin Sundarlal Chaudhari

Malini Bajpai

Laxmikant Atmaram Gharat

Vidya Ganapati Kattige

Shailesh Ramesh Pardeshi

Sanjib Das

Sanjay Margal

V S Prasada Rao Lingam

Rajendra L Harde

Bipin Parsottam Kansagra

Ashok Bhausaheb Kadam

V S Prasadarao Lingam

Suresh Mahadev Kadam

Sachin Vasantrao Dhone

Girish Gudi

Nayan Taterao Waghmare

Venkata Ramana Yemireddy

Vishal Govindrao Deshmukh

Sandeep Y Shelke

Javed Yusuf Khatik

Shantaram Kashinath Phatangare

Balasubramanian Gopalan

Gopalan Balasubramanian

Rajendra Prakash Chikhale

Ajit Shankar Mindhe

Dnyaneshwar E Shelke

Nisha Parag Patil

Ulhas R Dhuppad

Abhay Kulkarni

Vikram Mansingh Bhosale

Sukumar Sinha

Dinesh Pradeep Wale

Sachin Baban Gavhane

Srinivas Gullapalli

Sandeep Bandu Khandagale

Rajesh Kumar Dwivedi

Jayant Prakashrao Patil

Shailendra Nilkanth Bhadane

Shailesh Shrirang Pawase

Vaijnath Aravat

Bharat G Adik

Prashant Dilip Wadekar

Vidya Ganpati Kattige

Bhavna Mishra

Vs Prasada Rao Lingam

Deepak Vitthal Ukride

Meyyappan Muthuppalniappan

Prasada Rao V S Lingam

Deepak Vitthal Ukirde

Dattaguru Anandrao More

Someshwar Navhat

Neelima Khairatkar-joshi

Rajendra Laxman Harde

Sandeep Yadunath Shelke

Rajesh Dwivedi

Shailendra Bhadane

Shailesh Pawase

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R, R, R, R, R, R, R, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR&#x3b3;t). These compounds prevent, inhibit, or suppress the action of ROR&#x3b3;t and are therefore useful in the treatment of ROR&#x3b3;t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.

Compounds as ROR gamma modulators

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R, R, R, R, R, R, R, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR&#x3b3;t). These compounds prevent, inhibit, or suppress the action of ROR&#x3b3;t and are therefore useful in the treatment of ROR&#x3b3;t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer. 

The present disclosure is directed to novel carbocyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, R, n, m and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR&#x3b3;t). These compounds prevent, inhibit, or suppress the action of ROR&#x3b3;t and are therefore useful in the treatment of ROR&#x3b3;t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.

Carbocyclic compounds as ROR gamma modulators

The present disclosure is directed to novel carbocyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, R, n, m and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR&#x3b3;t). These compounds prevent, inhibit, or suppress the action of ROR&#x3b3;t and are therefore useful in the treatment of ROR&#x3b3;t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer. 

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Ring A, Ring B, R, R, R, n, and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR&#x3b3;t). These compounds prevent, inhibit, or suppress the action of ROR&#x3b3;t and are therefore useful in the treatment of ROR&#x3b3;t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer. 

Aryl and heteroaryl ether compounds as ROR gamma modulators

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X, X, M, R, R, R, R, m, n, and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR&#x3b3;t). These compounds prevent, inhibit, or suppress the action of ROR&#x3b3;t and are therefore useful in the treatment of ROR&#x3b3;t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, neurodegenerative diseases and cancer. 

Bicyclic heteroaryl indole analogues useful as ROR gamma modulators

The present invention is related to novel thienopyrimidinedione derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1. 

Thienopyrimidinedione derivatives as TRPA1 modulators

The present disclosure is directed to salts of N-{4-[2,4-difluoro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl}dimethyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-5-yl)acetamide and process for the preparation thereof (formula II). 

Amides of 2-amino-4-arylthiazole compounds and their salts

The present patent application relates to treatment of a respiratory disorder using TRPA1 antagonists. Particularly, the present patent application relates to treatment of a respiratory disorder using a TRPA1 antagonist, wherein the TRPA1 antagonist is administered by inhalation route to a subject in need thereof.

Treatment of respiratory disorders using TRPA1 antagonists

The present invention is related to 2-amino-4-arylthiazole derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1. 

2-amino-4-arylthiazole compounds as TRPA1 antagonists

The invention described herein relates to novel fused pyrimidinediones derivatives of formula (I) which are TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). This invention also provides processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1. 

Fused pyrimidine-dione derivatives as TRPA1 modulators

Growing community of inventors

Navi Mumbai, India

Abraham Thomas